FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2054016827> ?p ?o ?g. }

• W2054016827 endingPage "1612" @default.
• W2054016827 startingPage "1608" @default.
• W2054016827 abstract "The use of the immuno-suppressant cyclosporine A (CsA) after transplantation has been associated with less favorable plasma lipid profiles, which may contribute to the high incidence of cardiovascular morbidity and mortality in transplant recipients. Recent studies have suggested that oxidative modification of LDL plays an important role in the initiation and progression of atherosclerosis. It has also been demonstrated that CsA may facilitate lipid peroxidation in vitro and in vivo. Therefore, we determined several parameters of LDL oxidizability in renal transplant recipients who were switched from CsA to azathioprine (AZA)-based immunosuppressive treatment. The susceptibility of LDL to in vitro oxidation, LDL particle size, plasma titers of IgG and IgM antibodies against oxidized LDL and plasma LDL subclass patterns in 19 renal transplant recipients were determined during CsA treatment and 16 weeks after these patients were converted to AZA treatment. In addition, mean arterial pressure was recorded, and glomerular filtration rate and renal blood flow were estimated from the clearance of radiolabeled thalamate and hippurate. After conversion, the plasma concentrations of total cholesterol, LDL cholesterol and triglyceride decreased, while plasma HDL cholesterol did not change. During CsA therapy plasma LDL was significantly more susceptible to in vitro oxidation than during AZA, as reflected by a longer lag phase during in vitro oxidation (98.9 +/- 24.3 vs. 114.7 +/- 17.3 min, P = 0.031). In addition, the LDL size increased (236.5 +/- 7.3 vs. 240.7 +/- 6.8 nm, P = 0.00001), and the titers of IgM- and IgG-autoantibodies against oxidized LDL decreased significantly after patients were converted from CsA to AZA. The more atherogenic LDL subclass pattern B was present in 13 out of 19 patients during CsA. In five patients, pattern B changed into pattern A after conversion. The subclass B pattern was maintained in eight patients and subclass A pattern in six patients. In all patients the lag time of in vitro LDL oxidation increased, although the biggest changes were found in those patients in whom the LDL subclass changed from pattern B to pattern A. Mean arterial pressure decreased and renal function improved significantly after conversion. No correlation between parameters of lipid peroxidation and changes in blood pressure or renal function upon conversion, underlying renal disease, time since transplantation, or antihypertensive treatment was found. Our study demonstrates that treatment with CsA increases the susceptibility of LDL to in vitro oxidation, and also enhances the oxidation of LDL in vivo. In addition, conversion to AZA results in a more favorable lipid profile, which in combination with a lower arterial pressure and better renal function may decrease the risk for atherosclerosis. These factors may account for the cardiovascular complications during CsA treatment after organ transplantation, and also when CsA is used for other diseases." @default.
• W2054016827 created "2016-06-24" @default.
• W2054016827 creator A5011538150 @default.
• W2054016827 creator A5029735294 @default.
• W2054016827 creator A5031812273 @default.
• W2054016827 creator A5045196698 @default.
• W2054016827 creator A5067901119 @default.
• W2054016827 creator A5079004026 @default.
• W2054016827 date "1997-05-01" @default.
• W2054016827 modified "2023-10-16" @default.
• W2054016827 title "Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients" @default.
• W2054016827 cites W1966628044 @default.
• W2054016827 cites W1969138559 @default.
• W2054016827 cites W1977225672 @default.
• W2054016827 cites W1978356536 @default.
• W2054016827 cites W1978593398 @default.
• W2054016827 cites W1979846275 @default.
• W2054016827 cites W1990910626 @default.
• W2054016827 cites W1991348993 @default.
• W2054016827 cites W1991726504 @default.
• W2054016827 cites W1992085688 @default.
• W2054016827 cites W1995791052 @default.
• W2054016827 cites W1996810831 @default.
• W2054016827 cites W2018411580 @default.
• W2054016827 cites W2019265831 @default.
• W2054016827 cites W2023686366 @default.
• W2054016827 cites W2024938103 @default.
• W2054016827 cites W2027650214 @default.
• W2054016827 cites W2029783166 @default.
• W2054016827 cites W2035472159 @default.
• W2054016827 cites W2051530231 @default.
• W2054016827 cites W2052082703 @default.
• W2054016827 cites W2053802334 @default.
• W2054016827 cites W2063642389 @default.
• W2054016827 cites W2064067566 @default.
• W2054016827 cites W2064179373 @default.
• W2054016827 cites W2065633930 @default.
• W2054016827 cites W2113209574 @default.
• W2054016827 cites W2116404316 @default.
• W2054016827 cites W2143805949 @default.
• W2054016827 cites W2161165626 @default.
• W2054016827 cites W2161188230 @default.
• W2054016827 cites W2166648967 @default.
• W2054016827 cites W2183193914 @default.
• W2054016827 cites W2212323528 @default.
• W2054016827 cites W2218787476 @default.
• W2054016827 cites W2284948208 @default.
• W2054016827 cites W2323841893 @default.
• W2054016827 doi "https://doi.org/10.1038/ki.1997.221" @default.
• W2054016827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9150480" @default.
• W2054016827 hasPublicationYear "1997" @default.
• W2054016827 type Work @default.
• W2054016827 sameAs 2054016827 @default.
• W2054016827 citedByCount "52" @default.
• W2054016827 countsByYear W20540168272012 @default.
• W2054016827 countsByYear W20540168272014 @default.
• W2054016827 countsByYear W20540168272019 @default.
• W2054016827 countsByYear W20540168272021 @default.
• W2054016827 countsByYear W20540168272022 @default.
• W2054016827 crossrefType "journal-article" @default.
• W2054016827 hasAuthorship W2054016827A5011538150 @default.
• W2054016827 hasAuthorship W2054016827A5029735294 @default.
• W2054016827 hasAuthorship W2054016827A5031812273 @default.
• W2054016827 hasAuthorship W2054016827A5045196698 @default.
• W2054016827 hasAuthorship W2054016827A5067901119 @default.
• W2054016827 hasAuthorship W2054016827A5079004026 @default.
• W2054016827 hasBestOaLocation W20540168271 @default.
• W2054016827 hasConcept C126322002 @default.
• W2054016827 hasConcept C134018914 @default.
• W2054016827 hasConcept C159641895 @default.
• W2054016827 hasConcept C185592680 @default.
• W2054016827 hasConcept C2776151105 @default.
• W2054016827 hasConcept C2776760755 @default.
• W2054016827 hasConcept C2778163477 @default.
• W2054016827 hasConcept C2778913445 @default.
• W2054016827 hasConcept C2779134260 @default.
• W2054016827 hasConcept C2779620165 @default.
• W2054016827 hasConcept C2780829032 @default.
• W2054016827 hasConcept C2911091166 @default.
• W2054016827 hasConcept C71924100 @default.
• W2054016827 hasConceptScore W2054016827C126322002 @default.
• W2054016827 hasConceptScore W2054016827C134018914 @default.
• W2054016827 hasConceptScore W2054016827C159641895 @default.
• W2054016827 hasConceptScore W2054016827C185592680 @default.
• W2054016827 hasConceptScore W2054016827C2776151105 @default.
• W2054016827 hasConceptScore W2054016827C2776760755 @default.
• W2054016827 hasConceptScore W2054016827C2778163477 @default.
• W2054016827 hasConceptScore W2054016827C2778913445 @default.
• W2054016827 hasConceptScore W2054016827C2779134260 @default.
• W2054016827 hasConceptScore W2054016827C2779620165 @default.
• W2054016827 hasConceptScore W2054016827C2780829032 @default.
• W2054016827 hasConceptScore W2054016827C2911091166 @default.
• W2054016827 hasConceptScore W2054016827C71924100 @default.
• W2054016827 hasIssue "5" @default.
• W2054016827 hasLocation W20540168271 @default.
• W2054016827 hasLocation W20540168272 @default.
• W2054016827 hasOpenAccess W2054016827 @default.
• W2054016827 hasPrimaryLocation W20540168271 @default.

• next